The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al by S. Piantoni et al.
LETTER TO THE EDITOR
The rationale for the use of colchicine in COVID-19: comments
on the letter by Cumhur Cure M et al.
Silvia Piantoni1,2 & Enrico Colombo3 & Paolo Airò1 & Angela Tincani1,2 & Antonio Brucato4 & Franco Franceschini1,2 &
Laura Andreoli1,2 & Roberto Furloni3 & Mirko Scarsi3
Received: 20 May 2020 /Revised: 20 May 2020 /Accepted: 9 June 2020
# International League of Associations for Rheumatology (ILAR) 2020
Dear Editor,
We read with great interest the letter by Cumhur CureM et al.,
who raised several points of concern about the use of colchi-
cine for the treatment of severe acute respiratory syndrome
coronavirus 2 infection disease (COVID-19) [1]. However,
by considering the experience with colchicine in clinical prac-
tice and its mechanisms of action , we respectfully disagree
with their suggestion of discouraging the use of this drug in
COVID-19 [2]. On the contrary, there may be a rationale for
investigating its beneficial effects.
Recent observational studies underlined the effectiveness
of blocking the COVID-19-mediated cytokine storm by
targeting interleukin (IL)-1 and IL-6 in patients with
hyperinflammatory syndrome [3]. High-dose intravenous
anakinra was used in 29 patients with severe cytokine storm
with 89% of survival rate [4]. One hundred patients with se-
vere COVID-19 pneumonia and acute respiratory failure were
treated with tocilizumab, with a rapid and sustained response
in 77% of them [5].
Therefore, the management of COVID-19 should aim at
early identification and treatment of hyperinflammation in or-
der to prevent the cytokine storm. In this view, colchicine may
be a drug with potential effects in the early phase of COVID-
19-mediated inflammation. In fact, colchicine can prevent and
treat the flares of many autoinflammatory diseases character-
ized by aberrant IL-1/IL-6 pathway activation [6]. Notably,
colchicine can block the activation of NACHT-LRRPYD-
containing protein 3 (NLRP3) inflammasome, which was
demonstrated to be directly induced by the viroporin-E of
SARS-CoV [7]. The effectiveness of colchicine has been al-
ready reported in COVID-19 patients, even in the presence of
hemodynamic complications, such as cardiac tamponade [8],
and acute renal injury in a kidney transplant recipient [9].
Besides hyperinflammation, disseminated intravascular co-
agulation (DIC) and increased occurrence of cardiovascular
events are complications of COVID-19 [3, 10]. These might
be justified by the presence of endothelial cell infection and
endothelitis [11]. Endothelial cell damage can be found also in
Behçet’s disease (BD), an autoinflammatory disease charac-
terized by neutrophil activation, increased oxidative stress,
and generation of a thrombophilic status [12]. Colchicine is
largely used in BD, in which it may be useful also for
inflammation-induced thrombosis [13]. Furthermore, colchi-
cine was able to reduce the recurrence of secondary cardio-
vascular events after myocardial infarction, thanks to the in-
hibition of oxidative stress on the endothelium due to inflam-
matory cytokines [14]. These studies provide a rationale for a
possible role of colchicine in the prevention of coagulation
activation and thrombosis in COVID-19.
On the other hand, Cumhur CureM et al. hypothesized that
colchicine might emphasize SARS-CoV2 infection. This is in
contrast with in vitro and animal studies in which colchicine-
mediated cytoskeleton blockadewas able to reduce cell-to-cell
transfection during coronavirus infection, thus limiting the
viral load [15]. They hypothesized also that colchicine toxic
effects might increase the risk of DIC and acute respiratory
distress, but in clinical practice this might be relevant only in
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very rare cases of drug hyperdosage, while virus-specific
mechanisms are likely to be much more important. Indeed, it
should be remarked that, despite its narrow therapeutic win-
dow, the risk of serious drug-related toxic effects is minimal
for medium–low doses of colchicine (0.5–1 mg daily) [9, 16].
In conclusion, in our opinion, the risk–benefit ratio might
be favorable for colchicine as a candidate drug for COVID-19.
This assumption is supported by different experimental
models and extensive clinical experience in autoinflammatory
diseases, which did not raise any concern about the safety of
this drug. Based on this rationale, several trials are ongoing in
different countries to investigate the role of colchicine in the
treatment of COVID-19 (Canada [ClinicalTrials.gov
Identifier: NCT04322682]; Italy [NCT04375202 and
NCT04322565] ; Greece [NCT04326790] ; Spa in
[NCT04350320]; Argentina [NCT04328480]; Iran
[NCT04360980]; USA [NCT04355143 and NCT04363437]).
The manuscript does not contain clinical studies or patient
data.
Compliance with ethical standards
Disclosures None.
Code availability Not applicable.
Ethics approval Not applicable.
References
1. Cumhur Cure M, Kucuk A, Cure E (2020) Colchicine may not be
effective in COVID-19 infection; it may even be harmful? Clin
Rheumatol 39:2101–2102. https://doi.org/10.1007/s10067-020-
05144-x
2. Piantoni S, Patroni A, Toniati P et al (2020) Why not to use colchi-
cine in COVID-19? An old anti-inflammatory drug for a novel
auto-inflammatory disease. Rheumatology. https://doi.org/10.
1093/rheumatology/keaa217
3. Mehta P, McAuley DF, Brown M, On behalf of the HLH Across
Speciality Collaboration, UK et al (2020) COVID-19: consider cy-
tokine storm syndromes and immunosuppression. Lancet 395:
1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0
4. Cavalli G, De Luca G, Campochiaro C et al (2020) Interleukin-1
blockade with high-dose anakinra in patients with COVID-19,
acute respiratory distress syndrome, and hyperinflammation: a ret-
rospective cohort study. Lancet Rheumatol 2:e325–e331. https://
doi.org/10.1016/S2665-9913(20)30127-2
5. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F,
Franceschini F, Airò P, Bazzani C, Beindorf EA, Berlendis M,
Bezzi M, Bossini N, Castellano M, Cattaneo S, Cavazzana I,
Contessi GB, Crippa M, Delbarba A, de Peri E, Faletti A,
Filippini M, Filippini M, Frassi M, Gaggiotti M, Gorla R, Lanspa
M, Lorenzotti S, Marino R, Maroldi R, Metra M, Matteelli A,
Modina D, Moioli G, Montani G, Muiesan ML, Odolini S, Peli E,
Pesenti S, Pezzoli MC, Pirola I, Pozzi A, Proto A, Rasulo FA,
Renisi G, Ricci C, Rizzoni D, Romanelli G, Rossi M, Salvetti M,
Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR,
Turla F, Valsecchi A, Zani D, Zuccalà F, Zunica F, Focà E,
Andreoli L, Latronico N (2020) Tocilizumab for the treatment of
severe COVID-19 pneumonia with hyperinflammatory syndrome
and acute respiratory failure: a single center study of 100 patients in
Brescia, Italy. AutoimmunRev 19:102568. https://doi.org/10.1016/
j.autrev.2020.102568
6. Leung YY, Hui LLY, Kraus VB (2015) Colchicine-update on
mechanism of action and therapeutic uses. Semin Arthritis Rheum
45:341–350
7. Chen IY,MoriyamaM, ChangMF, Ichinohe T (2019) Severe acute
respiratory syndrome coronavirus viroporin 3a activates the
NLRP3 inflammasome. Front Microbiol 10:50
8. DabbaghMF, Aurora L, D'Souza P et al (2020) Cardiac tamponade
secondary to COVID-19. JACC Case Rep. https://doi.org/10.1016/
j.jaccas.2020.04.009
9. Gandolfini I, Delsante M, Fiaccadori E, Zaza G, Manenti L, Degli
Antoni A, Peruzzi L, Riella LV, Cravedi P, Maggiore U (2020)
COVID-19 in kidney transplant recipients. Am J Transplant.
https://doi.org/10.1111/ajt.15891
10. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P,
Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M,
Liu Y, Zheng D, Leibbrandt A,Wada T, Slutsky AS, Liu D, Qin C,
Jiang C, Penninger JM (2005) A crucial role of angiotensin
converting enzyme 2 (ACE2) in SARS coronavirus–induced lung
injury. Nat Med 11(8):875–879
11. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,
Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F,
Moch H (2020) Endothelial cell infection and endothelitis in
COVID-19. Lancet 395(10234):1417–1418
12. BecattiM, EmmiG, Silvestri E, Bruschi G, Ciucciarelli L, Squatrito
D, Vaglio A, Taddei N, Abbate R, Emmi L, Goldoni M, Fiorillo C,
Prisco D (2016) Neutrophil activation promotes fibrinogen oxida-
tion and thrombus formation in Behçet disease. Circulation 133(3):
302–311
13. Nonaka D, Takase H, Machii M, Ohno K (2020) Colchicine ther-
apy for deep vein thrombosis in a patient with vascular-type Behçet
disease: a case report. Medicine (Baltimore) 99(16):e19814
14. Tardif JC, Kouz S,Waters DD, BertrandOF, Diaz R,Maggioni AP,
Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón
J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA,
Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A,
L’Allier PL, Guertin MC, Roubille F (2019) Efficacy and safety
of low-dose colchicine after myocardial infarction. N Engl J Med
381(26):2497–2505
15. Milewska A, Nowak P, Owczarek K et al (2018) Entry of human
coronavirus NL63 into the cell. J Virol 92(3):e01933–17
16. Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC (2020)
Adverse events during oral colchicine use: a systematic review and
meta-analysis of randomised controlled trials. Arthritis Res Ther
22(1):28
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Clin Rheumatol
